Loading organizations...
§ Private Profile · Scottsdale, AZ, USA
Neurodiagnostics company developing diagnostic tools for neurodegenerative diseases, focused on Parkinson's and synucleinopathies.
Based in Scottsdale, Arizona, CND Life Sciences develops evidence-based diagnostic tools for neurodegenerative diseases by detecting pathological markers like phosphorylated alpha-synuclein in skin nerve fibers. The company operates a CLIA-certified and CAP-accredited laboratory, providing its flagship Syn-One Test to clinicians and biopharma collaborators to aid in the accurate diagnosis of Parkinson's disease, dementia with Lewy bodies, and related synucleinopathies. Operating under the leadership of Chief Executive Officer Richard J. Morello, the enterprise maintains a workforce of 100 employees and generates approximately $21 million in annual revenue. The neurodiagnostics firm has raised $12.5 million in total venture funding, which includes a seed round led by investor Peter Harris, who serves on the board of directors alongside Enrique Carrazana and Jack Seaver. CND Life Sciences was founded in 2017 by medical doctors Todd Levine, Christopher Gibbons, and Roy Freeman.
CND Life Sciences has raised $21.9M across 4 funding rounds.
CND Life Sciences has raised $21.9M in total across 4 funding rounds.
CND Life Sciences has raised $21.9M across 4 funding rounds. Most recently, it raised $13.5M Series A in May 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 14, 2025 | $13.5M Series A | Daniel Livschutz | — | Announced |
| Apr 6, 2023 | $1M Seed Plus | Patrick LEE | — | Announced |
| Feb 3, 2022 | $5M Seed | — | — | Announced |
| Mar 24, 2021 | $2.4M Seed | Peter Harris | Honorhealth | Announced |
CND Life Sciences has raised $21.9M in total across 4 funding rounds.
CND Life Sciences's investors include Daniel Livschutz, Patrick Lee, Peter Harris, HonorHealth.